摘要
目的观察黄芪注射液联合薄芝糖肽注射液治疗结肠癌术后患者的临床疗效。方法选取我院2011年1月至2013年1月收治的经影象学和病理学确诊为结肠癌的患者共70例,将其随机分为观察组和对照组。对照组在术后第2天行常规西药治疗,观察组在术后第2天行黄芪注射液联合薄芝糖肽注射液治疗,疗程为2个月。观察和比较两组患者生存质量、临床疗效和白细胞计数。结果治疗后,观察组的临床总效率为88.6%,生活质量改善有效率为91.4%,均显著高于对照组(P<0.05),且白细胞计数明显低于对照组(P<0.05)。结论黄芪注射液联合薄芝糖肽注射液能有效改善结肠癌术后患者的生活质量,临床疗效明显。
Objective To explore the clinical effects of astragalus injection combined with Bozhi glycopeptide injection in treating postoperative colon cancer. Methods We selected 70 cases that diagnosed as colon cancer through imaging and pathlogy from January 2012 to January 2013. All patients were divided randomly into the observation group and the control group. At d2 after surgery, the control group was treated with conventional western medicine, and the observation group was treated with astragalus injection combined with Bbozhi glycopeptide injection, all for two months. Then compare the survival quality, clinical efficacy, and white blood cells count between the two groups. Results The clinical total effect rate was 88.6% in the observation group, significantly higher than in the control group（P〈0.05）. The rate of life quality improvement in the observation group was 91.4%, also higher than that in the control group（P〈0.05）. Besides, the white blood cell counts was statistically lower in the observation group than in the control group（P〈0.05）. Conclusion Astragalus injection combined with Bozhi glycopeptide injection can improve the life quality of postoperative colon cancer patients with obvious clinical efficacy.
出处
《肿瘤药学》
CAS
2015年第2期142-145,共4页
Anti-Tumor Pharmacy
基金
湖南省卫生厅科技计划项目资助(B2012-091)
关键词
黄芪注射液
薄芝糖肽注射液
结肠癌
临床疗效
生存质量
Astragalus injection
Bozhi glycopeptide injection
Colon cancer
Clinical efficacy
Quality of life
作者简介
作者简介：柳红，女，副主任药师，研究方向：临床药学，E—mail：liuhong222@hotmail．com。
通讯作者：任华益，男，教授、主任药师，研究方向：肿瘤药理学与合理用药，E-mail：ren_huayi@163.com。
